Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Actavis Inc       US9426831031

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Company
Actavis plc operates as an investment holding company.It is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand, brand generic, over-the-counter and biosimilar products.The company was founded on October 1, 2013 and is... 
Sector
Pharmaceuticals
Calendar
11/05Earnings Release
Surperformance© rating of Actavis Inc
Trading Rating : Investor Rating :
More about the company
Financials ($)
Sales 2014 12 558 M
EBIT 2014 3 761 M
Net income 2014 1 799 M
Debt 2014 14 969 M
Yield 2014 -
Sales 2015 15 384 M
EBIT 2015 5 426 M
Net income 2015 2 755 M
Debt 2015 11 002 M
Yield 2015 -
PER 2014 40,90
PER 2015 21,01
EV / Sales 2014 6,22x
EV / Sales 2015 4,82x
Capitalization 63 100 M
More Financials
Latest news on ACTAVIS INC
6d agoDJPfizer Results Will Play Second Fiddle to Dealmaking Outlook -- Earnings Prev..
10/23 ACTAVIS : Confirms Appeals Court Upholds Lo Loestrin® Fe Patent
10/22 ACTAVIS : Signs Option to Acquire Rhythm Subsidiary and its GI Development Produ..
10/22 ACTAVIS : Signs Option to Acquire Rhythm Subsidiary and its GI Development Produ..
10/20 Actavis, Sanofi among bidders for Omega Pharma- Bloomberg
10/20 Top Allergan holder Paulson urges deal with Shire - sources
10/20 TOP ALLERGAN HOLDER PAULSON URGES DE : sources
10/16 ACTAVIS : Confirms Generic Quillivant XR® Patent Challenge
10/10 EXCLUSIVE - TOP ACTAVIS HOLDER, FIDE : sources
10/09 Allergan raises outlook; says Valeant offer undervalues company
10/09 ACTAVIS : Ironwood and Actavis to Present Linaclotide Data at the American Colle..
10/07 EXCLUSIVE : Actavis plans new merger approach for Allergan - sources
More news
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF